EPM
HZNP

Equitec Proprietary Markets’s Horizon Therapeutics Public Limited Company Ordinary Shares HZNP Stock Holding History

Equitec Proprietary Markets’s Portfolio HZNP Stock Details HZNP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q3 		– Sell
-6,550
Closed -$704K – 158
2023
Q2 		$674K Buy
+6,550
New +$691K 0.2% 51

Other funds holding HZNP

IA
IFP Advisors Tampa, Florida $4.82B AUM 20.19% 1-Year Est. Return
BTI
Blue Trust Inc Alpharetta, Georgia $8.74B AUM 14.62% 1-Year Est. Return
VWA
Valued Wealth Advisors Holladay, Utah $247M AUM 21.93% 1-Year Est. Return
FSWA
Financial Synergies Wealth Advisors Houston, Texas $1.18B AUM 31.41% 1-Year Est. Return
BCMLT
Beacon Capital Management LLC (Tennessee) Franklin, Tennessee $567M AUM 16.01% 1-Year Est. Return
HNB
Huntington National Bank Columbus, Ohio $18.1B AUM 24.69% 1-Year Est. Return

Equitec Proprietary Markets's HZNP Position: Q3 2023 in Review

Equitec Proprietary Markets sold out of Horizon Therapeutics Public Limited Company Ordinary Shares (HZNP) in Q3 2023, closing a stake of 6,550 shares — an estimated $704K sold.

Equitec Proprietary Markets first reported a position in HZNP in Q2 2023 and held it in 1 quarter. The position peaked at $674K in Q2 2023. 485 funds tracked by Wall St. Rank hold HZNP as of Q3 2023.

  • Equitec Proprietary Markets reported no remaining Horizon Therapeutics Public Limited Company Ordinary Shares position as of Q3 2023 after selling out during the quarter.
  • Equitec Proprietary Markets sold 6,550 Horizon Therapeutics Public Limited Company Ordinary Shares shares in Q3 2023, an estimated $704K.
  • Equitec Proprietary Markets first reported a position in Horizon Therapeutics Public Limited Company Ordinary Shares in Q2 2023 and held it in 1 quarter.
  • Equitec Proprietary Markets's Horizon Therapeutics Public Limited Company Ordinary Shares position peaked at $674K in Q2 2023.
  • 485 funds tracked by Wall St. Rank held Horizon Therapeutics Public Limited Company Ordinary Shares as of Q3 2023.

Based on Equitec Proprietary Markets's 13F filing for Q3 2023, filed 17 Oct 2023.